Literature DB >> 6213349

On the disulfiram-like activity of moxalactam.

R M Elenbaas, J L Ryan, W A Robinson, M J Singsank, M J Harvey, C D Klaassen.   

Abstract

A three-way crossover study was undertaken in 10 healthy subjects to characterize the reported disulfiram-like activity of moxalactam and to assess its influence on ethanol and acetaldehyde metabolism. On different occasions separated by at least 2 wk subjects were given in random order: 0.5 gm/kg ethanol orally, 0.5 gm/kg ethanol followed in 1 hr by 1.0 gm IV moxalactam, and 1.0 gm IV moxalactam every 8 hr for four doses followed by 0.5 gm/kg ethanol. Mean ethanol elimination rates of 13.1 +/- 0.76, 10.1 +/- 1.11, and 10.9 +/- 1.06 mg/dl/hr (mean +/- SEM) were observed in the three protocols, respectively. Corresponding mean estimated acetaldehyde clearance rates were 103.7 +/- 15.55, 92.8 +/- 13.79, and 97.3 +/- 10.41 l/min (mean +/- SEM). While no consistent moxalactam effect on ethanol or acetaldehyde elimination was observed, two subjects experienced mild disulfiram-like reactions to ethanol after moxalactam pretreatment. In one subject this reaction was associated with markedly elevated blood acetaldehyde concentrations. We conclude that moxalactam pretreatment may induce a disulfiram-like reaction after ethanol ingestion in some, probably due to inhibition of aldehyde dehydrogenase, and that alcoholic beverages are contraindicated in patients receiving moxalactam. We suggest, however, that such reactions will not occur when moxalactam is given after ethanol ingestion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213349     DOI: 10.1038/clpt.1982.170

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Disulfiram inhibits the in vitro growth of methicillin-resistant staphylococcus aureus.

Authors:  M Phillips; G Malloy; D Nedunchezian; A Lukrec; R G Howard
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 2.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

4.  Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia.

Authors:  S S Kline; V F Mauro; R B Forney; E H Freimer; P Somani
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.